Jacob Rosenberg, MBA
With more than 24 years of leadership experience designing and executing global registrational pivotal trials, Jacob has a proven track record of building and executing strategic development plans, establishing high-value partner relationships, and delivering clinical programs that meet the highest standards of safety, quality, and regulatory readiness. Jacob has served in progressively senior roles at […]
Viktoriya Megrabova
Viktoriya is an accomplished Regulatory Affairs leader with over a decade of experience in the pharmaceutical and biotech industries, and a specialized focus on allogeneic cell therapies and advanced biologics. She has consistently led the development and execution of regulatory strategies to support program advancement and potential commercialization, with a goal of achieving successful IND, […]
Janine Powers, PhD
Dr. Powers is an experienced leader in translational medicine with expertise advancing drug development across diverse therapeutic areas. With a strong background in both drug discovery and clinical development, Janine has successfully led high-performing teams to design and implement cutting-edge biomarker strategies in clinical trials. She brings extensive experience in multiple therapeutic modalities, including cell […]
James Adams, MBA
James has 30 years of operational experience across a wide range of disciplines including research and development, manufacturing, quality operations, and marketing and sales. He most recently served as Vice President of Manufacturing at Sonoma Biotherapeutics where he created a technical operations team in support of developing cell therapies targeting autoimmune disorders. Prior to joining […]
Marco Londei, MD
Dr. Londei most recently was the Chief Executive Officer of Gadeta. Prior to Gadeta, he was the Chief Development Officer and Chief Medical Officer of AnaptysBio (NASDAQ: ANAB), where he played a crucial role in the company’s transition from its preclinical phase to its successful IPO, and several rounds of financing as a clinical stage […]
Jonathan Perrin, JD
Jonathan serves as Tr1X’s General Counsel & Head of Operations. Prior to joining Tr1X, he was a partner at Massumi & Consoli LLP, a boutique law firm specializing in private equity M&A. Prior to MCLLP, he was a member of the Technology Companies & Life Sciences group at Goodwin Procter. Jon has represented venture-backed clients […]
Maria Grazia Roncarolo, MD
Maria Grazia is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, founder of the Center for Definitive and Curative Medicine, and former co-director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. Dr. Roncarolo has spent her career translating discoveries in immune-mediated […]
David de Vries, MPhil
David has over a decade of experience founding and scaling companies at the intersection of healthcare and technology. Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at Proteus Digital Health, one of […]